CVRx Reports Strong Preliminary Q1 2026 Results and Key Operational Updates
CVRx Reports Strong Preliminary Q1 2026 Results and Key Operational Updates
Key Highlights for Investors
- Preliminary Q1 2026 Revenue: Expected between \$14.7 million and \$14.8 million, representing approximately 20% year-over-year growth compared to \$12.3 million in Q1 2025.
- Gross Margin Improvement: Gross margin for Q1 2026 is expected to be approximately 87%, an increase from 84% in Q1 2025.
- Operating Expenses: Q1 2026 operating expenses are estimated at \$25 million, up from \$23.7 million in Q1 2025, reflecting continued investment in growth and market access initiatives.
- Cash Position: As of March 31, 2026, CVRx’s cash and cash equivalents stood at approximately \$72.3 million, providing a solid liquidity position.
- Growing U.S. Footprint: The number of active U.S. implanting centers increased to 257 (up from 252 at year-end 2025), with three additional sales territories added, bringing the total to 56 as of March 31, 2026.
Potentially Price-Sensitive Developments
-
Reimbursement Milestone:
- CVRx’s Barostim device transitioned to Category I Current Procedural Terminology (CPT) codes as of January 1, 2026, replacing Category III codes. This change is significant as it eliminates many automatic denials by payors, improves prior authorization predictability, and allows for more consistent and fair physician reimbursement for the procedure.
- Early 2026 data shows a substantial increase in the 30-day approval rate for Medicare Advantage prior authorizations handled by CVRx’s market access team: rising from 31% in 2024 to 44% in 2025, and now up to 50% for the first two months of 2026. This is a critical operational milestone that could accelerate adoption and revenue growth, a key factor for shareholders to watch closely.
-
BENEFIT-HF Clinical Trial Initiation:
- On March 31, 2026, the first site was activated in the landmark BENEFIT-HF clinical trial, with patient enrollment expected to begin in Q2 2026.
- The trial aims to evaluate Barostim’s impact on all-cause mortality and heart failure decompensation events in an expanded cohort of heart failure patients (left ventricular ejection fractions up to 50% and NT-proBNP levels up to 5,000 pg/mL).
- If successful, BENEFIT-HF could potentially triple Barostim’s indicated patient population, substantially broadening the device’s market opportunity—a development that could have significant positive implications for future revenue and share valuation.
Strategic and Financial Overview
CVRx’s President and CEO, Kevin Hykes, commented that the company’s 2025 investments in team expansion and program development are now producing tangible results, as seen in the strong Q1 revenue growth. He also highlighted that the implementation of the Category I CPT code is already reducing barriers to adoption and improving market access for Barostim.
The company continues to strengthen its U.S. presence with an increasing number of implanting centers and sales territories, and maintains a robust cash position to support its commercial and clinical initiatives.
Barostim remains the company’s flagship and only FDA-approved product for heart failure, and it also holds CE Mark approval for heart failure and resistant hypertension in the EU. The company is still dependent on this single product, which presents both opportunity and risk.
Risks and Forward-Looking Statements
CVRx’s management cautions that these preliminary results are unaudited and subject to adjustments following the completion of financial closing procedures. The company also notes ongoing risks, including dependence on a single product, the need for continued payor reimbursement, competition, and the outcome of the BENEFIT-HF trial, among others. Full Q1 2026 financial results are expected to be released in mid-May.
Contact Information
Disclaimer: This article is based on preliminary unaudited financial and operational results as released by CVRx, Inc. Final results may differ from those discussed herein. This article is for informational purposes only and does not constitute investment advice. Investors should review the company’s official filings and consult with their financial advisors before making any investment decisions.
View CVRx, Inc. Historical chart here
